Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
4.59 USD | +11.68% | +15.29% | -5.74% |
Financials (USD)
Sales 2024 * | 116M | Sales 2025 * | 137M | Capitalization | 203M |
---|---|---|---|---|---|
Net income 2024 * | -41M | Net income 2025 * | -26M | EV / Sales 2024 * | 1.64 x |
Net cash position 2024 * | 12.67M | Net cash position 2025 * | 14.68M | EV / Sales 2025 * | 1.37 x |
P/E ratio 2024 * |
-4.9
x | P/E ratio 2025 * |
-7.85
x | Employees | 330 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 52.79% |
Latest transcript on Akoya Biosciences, Inc.
1 day | +0.74% | ||
1 week | +3.79% | ||
Current month | +7.59% | ||
1 month | -2.61% | ||
3 months | -30.69% | ||
6 months | +9.31% | ||
Current year | -15.78% |
Managers | Title | Age | Since |
---|---|---|---|
Brian McKelligon
CEO | Chief Executive Officer | 55 | 17-06-30 |
Johnny Ek
DFI | Director of Finance/CFO | 48 | 23-03-19 |
Pascal Bamford
CTO | Chief Tech/Sci/R&D Officer | - | 21-10-25 |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Shepler
CHM | Chairman | 67 | 15-10-31 |
Myla Lai-Goldman
BRD | Director/Board Member | 66 | 21-09-15 |
Director/Board Member | 67 | 19-08-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.02% | 0 M€ | 0.00% | - | |
0.02% | 0 M€ | 0.00% | - | |
0.00% | 0 M€ | +8.23% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-09 | 4.59 | +11.68% | 173 646 |
24-05-08 | 4.11 | +0.74% | 80,801 |
24-05-07 | 4.08 | -0.97% | 68,841 |
24-05-06 | 4.12 | +1.98% | 93,323 |
24-05-03 | 4.04 | +1.25% | 141,995 |
Delayed Quote Nasdaq, May 08, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.78% | 203M | |
+8.07% | 219B | |
+7.87% | 185B | |
+12.75% | 135B | |
-1.33% | 62.21B | |
+4.88% | 51.01B | |
+11.59% | 51.28B | |
+2.71% | 41.85B | |
+4.90% | 37.02B | |
+23.75% | 31.27B |
- Stock Market
- Equities
- AKYA Stock